The initiation of coverage by Exane BNP Paribas with a Neutral rating and a price target of $28 for Kenvue (NYSE:KVUE) is likely to have a neutral impact on the stock price in the short term. The rating suggests that the analyst believes the stock is fairly valued at the current price, and the price target indicates a potential upside. However, the Neutral rating also implies that there may be better investment opportunities elsewhere.